Deciphera Pharmaceuticals LLC, Lawrence, announces the appointment of Dr. James A. Bristol to its board of managers.

Bristol recently retired from Pfizer Inc., where he had worked since 2000 and had been senior vice president for worldwide discovery research since 2003. He previously spent 20 years working for the Parke-Davis Pharmaceutical Research Division of Warner-Lambert, which he left as vice president for discovery research.

“We are honored to have Dr. Bristol join our board and regard his joining as a testament to Deciphera’s significant advancement of its technology and kinase inhibitor portfolio over the last three years,” said Daniel Flynn, Deciphera’s president and chief executive officer. “Dr. Bristol will be a significant resource as we strategically grow the company, enter clinical trials and form alliances with key partners.”

Deciphera is a drug-discovery and drug-development company with two advanced programs expected to enter human trials next year: one addressing chronic myelogenous leukemia, and another for the treatment of melanomas, colon cancer and other cancers.

For more information, visit www.deciphera.com.